Carrie Carda, MD
Obstetrics & Gynecology · Poplar Bluff, MONPI 1992777957
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,725 of the $22,319 with a category attached, or 70.5%. AbbVie accounts for 80.0% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2020 at $12,160 and has fallen 92.8% since, to $876 in 2025. Among obstetrics & gynecology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $66.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Axonics, Inc.$1K
- Novo Nordisk$314
- Astellas Pharma US Inc$291
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$254
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
- plus $2K from 39 others
What the payments were for
- Speaking & faculty fees$15,72570%
- Travel & lodging$9434%
- Food & beverage$5,45424%
- Education$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORIAHNN$11,475
- Orilissa$4,375
- Axonics$771
- Bulkamid$636
- ON-Q* PUMP AND ACCESSORIES$143
How this compares
$22,319 in reported general payments places this provider in the 95th percentile of 750 obstetrics & gynecology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 85 | $101,104 |
| OzempicSemaglutide | 86 | $81,865 |
| TrulicityDulaglutide | 73 | $76,497 |
| LinzessLinaclotide | 52 | $29,515 |
| JardianceEmpagliflozin | 42 | $28,147 |
| FarxigaDapagliflozin Propanediol | 49 | $25,752 |
| MyrbetriqMirabegron | 40 | $24,546 |
| JanuviaSitagliptin Phosphate | 20 | $15,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,276 |
| TrintellixVortioxetine Hydrobromide | 26 | $12,496 |
| ProgesteroneProgesterone, Micronized | 445 | $9,808 |
| Emgality PenGalcanezumab-Gnlm | 14 | $9,633 |
| EliquisApixaban | 13 | $9,140 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,111 |
| VascepaIcosapent Ethyl | 14 | $7,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $185 | $177,601158 claims |
| Novo NordiskOzempic | $314 | $81,86586 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $26 | $40,09484 claims |
| AbbVieLinzess | $17,848 | $29,51552 claims |
| Astellas Pharma US IncMyrbetriq | $291 | $24,54640 claims |
| MerckJanuvia | $66 | $15,57520 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22 | $12,49626 claims |
| PfizerEliquis | $119 | $9,14013 claims |
| Johnson & JohnsonXarelto | $86 | $7,51213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 obstetrics & gynecology providers in Missouri.
Other obstetrics & gynecology in Poplar Bluff
- Thomas ShultzSpringfield$1.1M
- Becky LynnSaint Louis$231K
- Timothy HallIndependence$172K
- Craig McCoyMoberly$101K
- Richard GutknechtIndependence$65K
- Amanda CarrollFestus$55K
- Amy CarterKansas City$49K
- Megan SneedLees Summit$44K
- Kimberly LemoineSaint Louis$30K
- John McCarvilleBranson$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.